Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Read more about Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Read more about Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.